Syndax Pharmaceuticals Inc SNDX
We are a commercial-stage biopharmaceutical company advancing innovative cancer therapies. We currently have two commercially approved medicines, Revuforj® (revumenib) and Niktimvo (axatilimab-csfr), and a robust slate of clinical development programs designed to unlock the full potential of our first two products.
Revuforj is our first-in-class menin inhibitor that was approved by the U.S. Food and Drug Administration, or FDA, in November 2024 for the treatment of relapsed or refractory, or R/R, acute leukemia with a lysine methyltransferase 2A gene, or KMT2A, translocation in adult and pediatric patients one year old and older. In October 2025, Revuforj received a second approval from the FDA for the treatment of R/R acute myeloid leukemia, or AML, with a susceptible nucleophosmin 1 mutation, or NPM1m, in adult and pediatric patients one year and older who have no satisfactory alternative treatment options. We are also studying revumenib in combination with standard-of-care agents in NPM1m AML and KMT2A-rearranged, or KMT2Ar, acute leukemia across the treatment landscape, including in newly diagnosed patients. Additionally, we are exploring the potential for menin inhibition in the treatment of myelofibrosis, or MF.
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $172.4M | $23.7M | $0 | $0 | $139.7M | $1.5M | $1.5M | $1.5M | $2.1M | $1.2M |
| R&D | $258.8M | $241.6M | $163.0M | $118.5M | $88.2M | $50.4M | $43.0M | $60.1M | $48.2M | $31.7M |
| SG&A | $179.7M | $120.9M | $66.9M | $33.3M | $25.2M | $22.5M | $16.1M | $17.3M | $15.9M | $13.3M |
| Total operating expenses | $445.4M | $363.4M | $230.0M | $151.8M | $113.5M | $72.9M | $59.1M | $77.4M | $64.1M | $45.0M |
| Operating income | -$273.1M | -$339.7M | -$230.0M | -$151.8M | $26.2M | -$71.4M | -$57.5M | -$75.9M | -$62.0M | -$43.8M |
| Interest expense | $6.0K | $1.0K | $208.0K | $3.1M | $1.9M | $2.4M | — | — | — | — |
| Pre-tax income | -$285.0M | — | — | — | $24.9M | -$73.2M | -$56.0M | -$74.0M | -$60.8M | -$44.5M |
| Income tax | $433.0K | — | — | — | $0 | $0 | $0 | $0 | $0 | $0 |
| Net income | -$285.4M | -$318.8M | -$209.4M | -$149.3M | $24.9M | -$73.2M | -$56.0M | -$74.0M | -$60.8M | -$44.5M |
| EPS, basic | -3.29 | -3.72 | -2.98 | -2.46 | 0.48 | -1.87 | -1.84 | — | — | — |
| EPS, diluted | -3.29 | -3.72 | -2.98 | -2.46 | 0.46 | -1.87 | -1.84 | -2.92 | -2.90 | -3.22 |
| Shares, diluted (wtd. avg.) | 86.6M | 85.6M | 70.4M | 60.8M | 53.6M | 41.3M | 30.5M | — | — | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $134.9M | $154.1M | $295.4M | $74.4M | $222.0M | $115.2M | $24.6M | $33.8M | $35.2M | $23.8M |
| Short-term investments | $259.1M | $418.8M | $275.3M | $401.4M | $218.0M | $177.8M | $35.2M | $47.1M | $94.8M | $81.5M |
| Receivables | $38.0M | $7.6M | $0 | — | — | — | — | — | — | — |
| Inventory | $32.8M | $366.0K | $0 | — | — | — | — | — | — | — |
| Total current assets | $528.1M | $603.1M | $580.9M | $489.8M | $448.4M | $298.9M | $62.3M | $83.3M | $133.4M | $108.5M |
| Property, plant and equipment | $181.0K | $0 | $8.0K | $20.0K | $278.0K | $192.0K | $281.0K | $373.0K | $267.0K | $260.0K |
| Total assets | $529.7M | $724.8M | $612.9M | $497.2M | $449.7M | $300.6M | $63.5M | $83.9M | $137.2M | $109.0M |
| Accounts payable | $16.6M | $11.6M | $10.0M | $4.3M | $5.7M | $3.5M | $6.2M | $1.4M | $2.2M | $2.4M |
| Short-term debt | $350.0M | $337.9M | $0 | — | — | — | — | — | — | — |
| Total current liabilities | $120.1M | $103.5M | $58.1M | $29.1M | $20.7M | $18.9M | $18.4M | $16.1M | $15.8M | $10.4M |
| Total liabilities | $465.1M | $436.7M | $58.7M | $29.8M | $41.3M | $48.4M | $31.9M | $30.9M | $32.9M | $24.9M |
| Retained earnings | -$1.51B | -$1.22B | -$902.4M | -$693.0M | -$543.7M | -$568.6M | -$495.5M | -$439.4M | -$366.1M | -$305.3M |
| Total equity | $64.6M | $288.1M | $554.2M | $467.4M | $408.4M | $252.2M | $31.6M | $53.0M | $104.3M | $84.1M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$323.0M | -$274.9M | -$160.6M | -$133.7M | $29.1M | -$71.3M | -$50.6M | -$68.5M | -$47.4M | -$35.2M |
| Depreciation and amortisation | $6.0M | $8.0M | $12.0M | $33.0M | $43.0M | $90.0K | $92.0K | $78.0K | $76.0K | $89.0K |
| Stock-based compensation | $47.5M | $43.0M | $31.0M | $16.0M | $13.3M | $9.1M | $6.0M | $6.2M | $5.5M | $4.7M |
| Capital expenditure | $187.0K | $0 | $0 | $0 | $129.0K | $0 | — | $187.0K | $84.0K | $261.0K |
| Investing cash flow | $290.0M | -$219.8M | $117.6M | -$186.2M | -$40.9M | -$142.5M | $12.8M | $51.4M | -$17.1M | -$18.3M |
| Financing cash flow | $13.7M | $353.4M | $264.1M | $172.3M | $118.5M | $304.4M | $28.6M | $15.7M | $75.7M | $54.2M |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001193125-26-197859.
Plot the figures US dollars
- Revenue
- Gross profit
- Net income
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.2M | $2.1M | $1.5M | $1.5M | $1.5M | $139.7M | $0 | $0 | $23.7M | $172.4M |
| Gross profit | — | — | — | — | — | — | — | — | — | — |
| Net income | -$44.5M | -$60.8M | -$74.0M | -$56.0M | -$73.2M | $24.9M | -$149.3M | -$209.4M | -$318.8M | -$285.4M |
Recent filings and events
- Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
- Other event The catch-all. The company chose to disclose something that fits no other item, so the content is whatever it says it is. Item 8.01
- Material agreement signed The company entered an agreement outside the ordinary course of business - a large contract, a credit facility, a merger agreement. Item 1.01
- New debt or obligation The company has taken on debt or a comparable obligation. Item 2.03
- Unregistered share sale Shares issued outside a registered offering. Dilution, and for a small company often the way it is funded. Item 3.02
- Officer or director change Someone at the top arrived or left. The item covers everything from a board retirement to a chief executive being removed, and only the filing itself says which. Item 5.02
- Shareholder vote The results of the annual meeting or a special vote. Item 5.07
- Material agreement signed Item 1.01
- New debt or obligation Item 2.03
- Unregistered share sale Item 3.02
- Other event Item 8.01
- Results announced Item 2.02
Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.
Others in SIC 2834
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| LLY | ELI LILLY & Co | $1.20T | 55.7x | 44.7% |
| JNJ | JOHNSON & JOHNSON | $641.76B | 24.1x | 6.0% |
| ABBV | AbbVie Inc. | $506.70B | 121.5x | 8.6% |
| MRK | Merck & Co., Inc. | $346.91B | 19.3x | 1.3% |
| ABT | ABBOTT LABORATORIES | $182.68B | 28.2x | 5.7% |
| PFE | PFIZER INC | $169.79B | 21.9x | -1.6% |
| VRTX | VERTEX PHARMACEUTICALS INC / MA | $131.16B | 33.8x | 8.9% |
| BMY | BRISTOL MYERS SQUIBB CO | $125.85B | 17.8x | -0.2% |